Phase 2 N=8 FMT in Ulcerative Colitis-Associated Pouchitis
Ulcerative Colitis Associated Pouchitis
Primary: Number of Patients Who Experienced Improvement of Pouchitis Symptoms — 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis
Ulcerative Colitis
Primary: Percent of Participants With at Least a 3 Point Drop in the Short Clinical Colitis Score (SCCAI) — 63 Percent of participants
Phase 3 N=829 Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis
Ulcerative Colitis
Primary: Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months — 83.7; 81.5 percent of participants
Phase 1 N=20 Gut Microbial Transplantation in Pediatric Inflammatory Bowel Diseases
Inflammatory Bowel Disease (IBD)
Primary: Clinical Response — 9 Participants — p=0.03
Phase 2 N=15 Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis
Inflammatory Bowel Diseases · Ulcerative Colitis · Crohn Disease
Primary: 1. Safety and Tolerability of Universal Donor FMT Compared to Placebo: FMT-related Adverse Events Grade 2 or Above — 4; 0 Participants
Phase 2 N=164 A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.
Ulcerative Colitis
Primary: The Percentage of Subject Achieve Clinical Response at Week 8 — 46.3; 46.3; 43.9; 26.8 percentage of participants
Phase 1 N=18 Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission
Ulcerative Colitis
Primary: Number of Participants With Clinical Toxicity Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version (v.) 4.0 — 2; 0…
Phase 3 N=614 A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Participants With Remission at Week 8 — 18.5; 8.2 percentage of participants — p=0.0070
Phase 3 N=32 Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Patients Who Achieved Clinical Response — 57; 35 percentage of patients — p=0.05
Phase 2 N=179 Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
Ulcerative Colitis
Primary: Relapse Free Survival Week 17-48 — 12; 12 Participants
Phase 2 N=79 BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis
Colitis, Ulcerative
Primary: Exposure Adjusted Rate of Participants Reporting a Treatment Emergent Adverse Event (TEAE) — 260.6 Events per 100 patient-years
Phase 2 N=123 A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis
Active Ulcerative Colitis
Primary: Percentage of Participants With a Clinical Response — 53; 44 percentage of participants
Phase 3 N=121 A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)
Colitis, Ulcerative
Primary: Percentage of Participants With Clinical Remission at Week 54 Based on Modified Mayo Score — 51.1; 43.5 percentage of participants
Phase 3 N=98 BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis
Colitis, Ulcerative
Primary: Proportion of Patients With Clinical Remission at Week 12 — 0.00; 0.042; 0.087; 0.071 Proportion of Participants
Phase 3 N=961 A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Colitis, Ulcerative · Inflammatory Bowel Diseases
Primary: Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per Global Definition) — 17; 50; 50 Participants — p=< 0.001